SCHEMBL6535778

SCHEMBL6535778

Cc1cccc(-n2ccccc2=O)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.52
MGLL Q99685 1/20 0.52
L3MBTL1 Q9Y468 2/20 0.50
ALDH1A1 P00352 2/20 0.49
HPGD P15428 2/20 0.49
HSD17B10 Q99714 2/20 0.47
KDM4E B2RXH2 1/20 0.47
CYP1A2 P05177 1/20 0.47
BLM P54132 1/20 0.47
PMM2 O15305 1/20 0.45
MPI P34949 1/20 0.45
PHOSPHO1 Q8TCT1 1/20 0.45
ALKBH5 Q6P6C2 1/20 0.44
ALOX5 P09917 1/20 0.44
KMT2A Q03164 2/20 0.43
RAB9A P51151 1/20 0.43
MEN1 O00255 1/20 0.43
GAA P10253 1/20 0.43
CASP6 P55212 1/20 0.43
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17059032 0.84 COMT (0.49) HSP90AA1L3MBTL1ALDH1A1HPGDHSD17B10
SCHEMBL3302828 0.79 ALDH1A1 (0.70) HSP90AA1MGLLL3MBTL1ALDH1A1HPGD
SCHEMBL2222230 0.78 MGLL (0.50) MGLLALDH1A1PMM2MPIPHOSPHO1
SCHEMBL9292198 0.78 HSP90AA1 (0.49) HSP90AA1MGLLL3MBTL1ALDH1A1HPGD
SCHEMBL18050078 0.78 MGLL (0.54) MGLLALDH1A1HPGDKDM4ECYP1A2
SCHEMBL92819 0.78 KDM4E (0.57) MGLLALDH1A1HPGDHSD17B10KDM4E
SCHEMBL18050030 0.77 FGFR1 (0.47) L3MBTL1ALDH1A1HSD17B10KDM4EKMT2A
SCHEMBL13907449 0.77 KMT2A (0.53) ALDH1A1HPGDHSD17B10KDM4ECYP1A2
Amphenidone SCHEMBL586236 0.77 MAPT (0.57) ALDH1A1KDM4EKMT2AMEN1MAPT
SCHEMBL13672252 0.77 FAAH (0.52) MGLLL3MBTL1ALDH1A1MPIALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1138329-B1 Composition containing 5-Methyl-1-phenyl-2-(1 H)-pyridone for reparation and prevention of fibrotic lesions YAMAUCHI SHITOTOMO (JP) 2004-06-02 EP claimed
EP-0383591-B1 Use of 5-methyl-1-phenyl-2-(1H)-pyridone in the prevention of fibrotic lesions YAMAUCHI SHITOTOMO (JP) 2001-11-21 EP claimed
WO-2022081795-A9 ON DEMAND AND LONG-TERM DRUG DELIVERY FROM DEGRADABLE NANOCAPSULES UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) 2023-06-22 WO disclosed
WO-2023091479-A1 DETECTION AND TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS AmMax Bio, Inc. (US) 2023-05-25 WO disclosed
US-20230043159-A1 MATRIPTASE 2 INHIBITORS AND USES THEREOF DISC MEDICINE, INC. 2023-02-09 US disclosed
WO-2022081795-A2 ON DEMAND AND LONG-TERM DRUG DELIVERY FROM DEGRADABLE NANOCAPSULES UNIVERSITY OF MARYLAND, BALTIMORE COUNTY (US) 2022-04-21 WO disclosed
EP-3644983-A1 COMPOSITIONS AND METHODS OF TREATING OR PREVENTING FIBROTIC LUNG DISEASES Yale University (US) 2020-05-06 EP disclosed
US-20200016138-A1 GEL CONTAINING PIRFENIDONE EXCALIBUR PHARMACEUTICALS, INC. 2020-01-16 US disclosed
WO-2019005816-A1 COMPOSITIONS AND METHODS OF TREATING OR PREVENTING FIBROTIC LUNG DISEASES YALE UNIVERSITY (US) 2019-01-03 WO disclosed
WO-2018236698-A1 TRANSDERMAL CREAM FOR TREATING DUPUYTREN'S CONTRACTURE Advanced Fibrosis Research LLC (US) 2018-12-27 WO disclosed
US-20180360751-A1 Transdermal cream for treating Dupuytren's Contracture Advanced Fibrosis Research LLC (US) 2018-12-20 US disclosed
EP-3102703-A2 METHODS FOR TREATING FIBROTIC DISEASE Effector Therapeutics Inc. (US) 2016-12-14 EP disclosed
WO-2015191841-A1 NOVEL METHODS OF TREATING OR PREVENTING FIBROTIC LUNG DISEASES YALE UNIVERSITY (US) 2015-12-17 WO disclosed
WO-2015120350-A2 COMPOSITIONS AND METHODS FOR TREATING FIBROTIC DISEASE EFFECTOR THERAPEUTICS, INC. (US) 2015-08-13 WO disclosed
WO-2015118365-A1 NOVEL USE OF SIGMA-1 RECEPTOR AGONIST COMPOUNDS MTA TÁMOGATOTT KUTATÓCSOPORTOK IRODÁJA (HU) 2015-08-13 WO disclosed
EP-2670242-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF Genoa Pharmaceuticals, Inc. (US) 2013-12-11 EP disclosed
WO-2012106382-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF GENOA PHARMACEUTICALS, INC. (US) 2012-08-09 WO disclosed
EP-1261338-A4 COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY CYMAR INC (US) 2004-05-06 EP disclosed
EP-1261338-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY Cymar, Inc. (US) 2002-12-04 EP disclosed
WO-2001062253-A1 COMPOSITIONS AND METHODS FOR TREATMENT OF EPILEPSY CYMAR, INC. (US) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200016138-A1 GEL CONTAINING PIRFENIDONE PIR, COL1A1, CUTA HSP90AA1 110/4885MGLL 4261/4885L3MBTL1 4350/4885
US-20230043159-A1 MATRIPTASE 2 INHIBITORS AND USES THEREOF MMP7, MATR3, SPINT2 HSP90AA1 4083/4885MGLL 1457/4885L3MBTL1 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.